Perspective Therapeutics Reports Positive Phase 1/2a Trial Data for Neuroendocrine Tumors

Perspective Therapeutics announced encouraging incremental data from its ongoing Phase 1/2a clinical trial of [212Pb]Bamzireotide Navoxetan for advanced neuroendocrine tumors. The investigational therapy demonstrated durable disease control and positive responses, particularly in gastroenteropancreatic NET patients, while remaining well-tolerated. This early data supports continued development, offering potential new treatment options for patients with this challenging cancer.